{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:49:59Z","timestamp":1781754599578,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T00:00:00Z","timestamp":1386115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40261-013-0158-x","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T09:04:08Z","timestamp":1386061448000},"page":"63-80","source":"Crossref","is-referenced-by-count":83,"title":["Sodium Oxybate: A Review of Its Use in Alcohol Withdrawal Syndrome and in the Maintenance of Abstinence in Alcohol Dependence"],"prefix":"10.1007","volume":"34","author":[{"given":"Gillian M.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"issue":"2","key":"158_CR1","first-page":"135","volume":"34","author":"J Rehm","year":"2011","unstructured":"Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health. 2011;34(2):135\u201343.","journal-title":"Alcohol Res Health."},{"issue":"9662","key":"158_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","volume":"373","author":"MA Schuckit","year":"2009","unstructured":"Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492\u2013501.","journal-title":"Lancet."},{"issue":"9","key":"158_CR3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655\u201379.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"11","key":"158_CR4","first-page":"858","volume":"82","author":"R Kohn","year":"2004","unstructured":"Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858\u201366.","journal-title":"Bull World Health Organ."},{"key":"158_CR5","unstructured":"National Institute for Health and Clinical Excllence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011. http:\/\/www.nice.org.uk\/nicemedia\/live\/13337\/53191\/53191.pdf . Accessed 14 Oct 2013."},{"issue":"5","key":"158_CR6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","volume":"105","author":"J Rehm","year":"2010","unstructured":"Rehm J, Baliunas D, Borges GLG, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817\u201343.","journal-title":"Addiction."},{"issue":"5","key":"158_CR7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.pnpbp.2007.09.021","volume":"32","author":"L Leggio","year":"2008","unstructured":"Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome: a focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1106\u201317.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"2","key":"158_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","volume":"26","author":"J Chick","year":"2012","unstructured":"Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol (Oxf). 2012;26(2):205\u201312.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"158_CR9","unstructured":"Laboratorio Farmaceutico C.T. S.r.l. Alcover\u00ae (sodium oxybate; 4-hydroxybutyric acid sodium salt): Italian summary of product characteristics. 2007."},{"key":"158_CR10","unstructured":"G.L. Pharma GmbH. Alcover\u00ae (sodium gamma hydroxybutyric acid): Austrian summary of product characteristics. 2012."},{"issue":"Suppl 1","key":"158_CR11","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/alcalc\/agr099","volume":"46","author":"B Tabakoff","year":"2011","unstructured":"Tabakoff B. Neurobiology of GHB in relation to alcohol dependence [abstract no. SAT2.2]. Alcohol Alcohol. 2011;46(Suppl 1):i24.","journal-title":"Alcohol Alcohol."},{"issue":"Suppl 2","key":"158_CR12","first-page":"14A","volume":"19","author":"HL June","year":"1995","unstructured":"June HL, Williams JA, Cason CR, et al. Low doses of gamma-hydroxybutyric acid (GHB) attenuate ethanol intake in alcohol-preferring (P) rats [abstract no. 62]. Alcohol Clin Exp Res. 1995;19(Suppl 2):14A.","journal-title":"Alcohol Clin Exp Res."},{"issue":"26","key":"158_CR13","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1056\/NEJMra044047","volume":"352","author":"OC Snead","year":"2005","unstructured":"Snead OC, Gibson KM. \u03b3-Hydroxybutyric acid. N Engl J Med. 2005;352(26):2721\u201332.","journal-title":"N Engl J Med."},{"issue":"3","key":"158_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/01.wnl.0000341945.28830.88","volume":"72","author":"EE Benarroch","year":"2009","unstructured":"Benarroch EE. \u03b3-Hydroxybutyric acid and its relevance in neurology. Neurology. 2009;72(3):282\u20136.","journal-title":"Neurology."},{"issue":"1","key":"158_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","volume":"63","author":"KL Nicholson","year":"2001","unstructured":"Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63(1):1\u201322.","journal-title":"Drug Alcohol Depend."},{"key":"158_CR16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/BF00839786","volume":"108","author":"VG Treskov","year":"1989","unstructured":"Treskov VG, Krashkina II, Tsirenina ML, et al. Effect of sodium hydroxybutyrate on catecholamine and serotonin levels and monoamine oxidase activity in alcoholics. Bull Exp Biol Med. 1989;108:976\u20138.","journal-title":"Bull Exp Biol Med."},{"issue":"6","key":"158_CR17","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/ijerph6061917","volume":"6","author":"F Caputo","year":"2009","unstructured":"Caputo F, Vignoli T, Maremmani I, et al. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health. 2009;6(6):1917\u201329.","journal-title":"Int J Environ Res Public Health."},{"issue":"2","key":"158_CR18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1254\/jphs.FP0071487","volume":"106","author":"MAM Carai","year":"2008","unstructured":"Carai MAM, Lobina C, Maccioni P, et al. \u03b3-Aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of \u03b3-butyrolactone. J Pharmacol Sci. 2008;106(2):199\u2013207.","journal-title":"J Pharmacol Sci."},{"issue":"3","key":"158_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(02)01502-9","volume":"441","author":"MA Carai","year":"2002","unstructured":"Carai MA, Colombo G, Reali R, et al. Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into \u03b3-hydroxybutyric acid. Eur J Pharmacol. 2002;441(3):157\u201363.","journal-title":"Eur J Pharmacol."},{"issue":"33","key":"158_CR20","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1073\/pnas.1204376109","volume":"109","author":"N Absalom","year":"2012","unstructured":"Absalom N, Eghorn LF, Villumsen IS, et al. \u03b14\u03b2\u03b4 GABAA receptors are high-affinity targets for \u03b3-hydroxybutyric acid (GHB). Proc Natl Acad Sci USA. 2012;109(33):13404\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"158_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0741-8329(99)00091-9","volume":"20","author":"GL Gessa","year":"2000","unstructured":"Gessa GL, Agabio R, Carai MAM, et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol. 2000;20(3):271\u20136.","journal-title":"Alcohol."},{"key":"158_CR22","first-page":"281","volume":"47","author":"G Biggio","year":"1992","unstructured":"Biggio G, Cibin M, Diana M, et al. Suppression of voluntary alcohol intake in rats and alcoholics by gamma-hydroxybutyric acid: a non-GABAergic mechanism. Adv Biochem Psychopharmacol. 1992;47:281\u20138.","journal-title":"Adv Biochem Psychopharmacol."},{"issue":"4","key":"158_CR23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1369-1600.2000.tb00207.x","volume":"5","author":"G Colombo","year":"2000","unstructured":"Colombo G, Gessa GL. Gamma-hydroxybutyric acid in alcohol preference, dependence and withdrawal. Addict Biol. 2000;5(4):389\u2013403.","journal-title":"Addict Biol."},{"issue":"5","key":"158_CR24","first-page":"447","volume":"24","author":"F Fadda","year":"1989","unstructured":"Fadda F, Colombo G, Mosca E, et al. Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats. Alcohol Alcohol. 1989;24(5):447\u201351.","journal-title":"Alcohol Alcohol."},{"issue":"3","key":"158_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(94)00687-3","volume":"273","author":"G Colombo","year":"1995","unstructured":"Colombo G, Agabio R, Lobina C, et al. Cross-tolerance to ethanol and \u03b3-hydroxybutyric acid. Eur J Pharmacol. 1995;273(3):235\u20138.","journal-title":"Eur J Pharmacol."},{"issue":"5","key":"158_CR26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/alcalc\/33.5.465","volume":"33","author":"R Agabio","year":"1998","unstructured":"Agabio R, Colombo G, Loche A, et al. \u03b3-Hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism. Alcohol Alcohol. 1998;33(5):465\u201374.","journal-title":"Alcohol Alcohol."},{"issue":"2","key":"158_CR27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.alcohol.2008.01.001","volume":"42","author":"P Maccioni","year":"2008","unstructured":"Maccioni P, Pes D, Fantini N, et al. \u03b3-Hydroxybutyric acid (GHB) suppresses alcohol\u2019s motivational properties in alcohol-preferring rats. Alcohol. 2008;42(2):107\u201313.","journal-title":"Alcohol."},{"issue":"9490","key":"158_CR28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(05)67371-0","volume":"366","author":"F Caputo","year":"2005","unstructured":"Caputo F, Addolorato G, Trevisani F, et al. \u03b3-Hydroxybutyrate as a treatment for alcoholism. Lancet. 2005;366(9490):981\u20132.","journal-title":"Lancet."},{"key":"158_CR29","doi-asserted-by":"crossref","unstructured":"Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010.(2):CD006266.","DOI":"10.1002\/14651858.CD006266.pub2"},{"key":"158_CR30","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution CIII: US prescribing Information. 2012. http:\/\/www.xyrem.com\/images\/XYREM_PI.pdf . Accessed 14 Oct 2013."},{"key":"158_CR31","unstructured":"European Medicines Agency. Xyrem (sodium oxybate): EU summary of product characteristics. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000593\/WC500057103.pdf . Accessed 14 Oct 2013."},{"issue":"4","key":"158_CR32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","volume":"5","author":"YG Wang","year":"2009","unstructured":"Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5(4):365\u201371.","journal-title":"J Clin Sleep Med."},{"issue":"3","key":"158_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0404.2006.00712.x","volume":"114","author":"KR Drasbek","year":"2006","unstructured":"Drasbek KR, Christensen J, Jensen K. Gamma-hydroxybutyrate: a drug of abuse. Acta Neurol Scand. 2006;114(3):145\u201356.","journal-title":"Acta Neurol Scand."},{"issue":"3","key":"158_CR34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0741-8329(99)00084-1","volume":"20","author":"G Addolorato","year":"2000","unstructured":"Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid: efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol. 2000;20(3):217\u201322.","journal-title":"Alcohol."},{"issue":"4","key":"158_CR35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0735-6757(91)90050-T","volume":"9","author":"JE Dyer","year":"1991","unstructured":"Dyer JE. \u03b3-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med. 1991;9(4):321\u20134.","journal-title":"Am J Emerg Med."},{"issue":"1","key":"158_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2004.01.012","volume":"75","author":"M McDonough","year":"2004","unstructured":"McDonough M, Kennedy N, Glasper A, et al. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004;75(1):3\u20139.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"158_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0741-8329(99)00085-3","volume":"20","author":"F Begh\u00e8","year":"2000","unstructured":"Begh\u00e8 F, Carpanini MT. Safety and tolerability of gamma-hydroxybutyric acid in the treatment of alcohol-dependent patients. Alcohol. 2000;20(3):223\u20135.","journal-title":"Alcohol."},{"issue":"5","key":"158_CR38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","volume":"26","author":"D Thai","year":"2006","unstructured":"Thai D, Dyer JE, Benowitz NL, et al. GHB and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006;26(5):524\u20139.","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"158_CR39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1172\/JCI119587","volume":"100","author":"E Cauter Van","year":"1997","unstructured":"Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest. 1997;100(3):745\u201353.","journal-title":"J Clin Invest."},{"key":"158_CR40","doi-asserted-by":"crossref","unstructured":"Addolorato G, Capristo E, Gessa GL, et al. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sci. 1999;65(14):PL191\u20136.","DOI":"10.1016\/S0024-3205(99)00395-1"},{"issue":"11","key":"158_CR41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050560","volume":"54","author":"SD Ferrara","year":"1999","unstructured":"Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol. 1999;54(11):821\u20137.","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"158_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00213-009-1589-1","volume":"206","author":"LP Carter","year":"2009","unstructured":"Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl). 2009;206(1):141\u201354.","journal-title":"Psychopharmacology (Berl)."},{"issue":"3","key":"158_CR43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00952990701315046","volume":"33","author":"F Nava","year":"2007","unstructured":"Nava F, Premi S, Manzato E, et al. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse. 2007;33(3):379\u201392.","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"3","key":"158_CR44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/039463201002300320","volume":"23","author":"S Franchi","year":"2010","unstructured":"Franchi S, Sacerdote P, Moretti S, et al. The effects of alcoholism pharmacotherapy on immune responses in alcohol-dependent patients. Int J Immunopathol Pharmacol. 2010;23(3):847\u201355.","journal-title":"Int J Immunopathol Pharmacol."},{"issue":"3","key":"158_CR45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2125.1992.tb04129.x","volume":"34","author":"SD Ferrara","year":"1992","unstructured":"Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of \u03b3-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol. 1992;34(3):231\u20135.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 1","key":"158_CR46","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/alcalc\/agt095","volume":"48","author":"P Vivet","year":"2013","unstructured":"Vivet P, Pross N, Denot C, et al. Pharmacodynamic interactions of a solid formulation of sodium oxybate and alcohol in healthy volunteers [abstract no. SAT2.3]. Alcohol Alcohol. 2013;48(Suppl 1):i34.","journal-title":"Alcohol Alcohol."},{"key":"158_CR47","unstructured":"Data on file, D&A Pharma, 2013."},{"key":"158_CR48","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. revised. Washington, DC: American Psychiatric Association; 1987."},{"key":"158_CR49","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"key":"158_CR50","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (text revision). Washington, DC: American Psychiatric Association; 2000."},{"key":"158_CR51","volume-title":"International classification of diseases, 10th revision","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. International classification of diseases, 10th revision. Geneva: World Health Organization; 1992."},{"issue":"8666","key":"158_CR52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","volume":"2","author":"L Gallimberti","year":"1989","unstructured":"Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet. 1989;2(8666):787\u20139.","journal-title":"Lancet."},{"issue":"1","key":"158_CR53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/alcalc\/37.1.67","volume":"37","author":"AA Nimmerrichter","year":"2002","unstructured":"Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, et al. Double-blind controlled trial of \u03b3-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002;37(1):67\u201373.","journal-title":"Alcohol Alcohol."},{"issue":"10","key":"158_CR54","first-page":"1596","volume":"23","author":"G Addolorato","year":"1999","unstructured":"Addolorato G, Balducci G, Capristo E, et al. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine. Alcohol Clin Exp Res. 1999;23(10):1596\u2013604.","journal-title":"Alcohol Clin Exp Res."},{"issue":"3","key":"158_CR55","first-page":"83","volume":"30","author":"C Korninger","year":"2003","unstructured":"Korninger C, Roller RE, Lesch OM. Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital. Acta Med Austriaca. 2003;30(3):83\u20136.","journal-title":"Acta Med Austriaca."},{"issue":"3","key":"158_CR56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0741-8329(99)00093-2","volume":"20","author":"M Moncini","year":"2000","unstructured":"Moncini M, Masini E, Gambassi F, et al. Gamma-hydroxybutyric acid and alcohol-related syndromes. Alcohol. 2000;20(3):285\u201391.","journal-title":"Alcohol."},{"issue":"3","key":"158_CR57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/00952990902933852","volume":"35","author":"C Elsing","year":"2009","unstructured":"Elsing C, Stremmel W, Grenda U, et al. Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study. Am J Drug Alcohol Abuse. 2009;35(3):189\u201392.","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"4","key":"158_CR58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","volume":"16","author":"L Gallimberti","year":"1992","unstructured":"Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res. 1992;16(4):673\u20136.","journal-title":"Alcohol Clin Exp Res."},{"key":"158_CR59","doi-asserted-by":"crossref","unstructured":"Cacciaglia R, Lesch OM, Vivet P. GATE 2 study: sodium oxybate in the maintenance of alcohol abstinence and prevention of alcohol relapse [abstract no. P30]. Alcohol Alcohol. 2013;48 Suppl 1:i47\u20138 plus poster presented at the 14th Congress of the European Society for Biomedical Research on Alcoholism; 8\u201311 Sep 2013; Warsaw.","DOI":"10.1093\/alcalc\/agt120"},{"issue":"3","key":"158_CR60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02791072.2006.10399846","volume":"38","author":"F Nava","year":"2006","unstructured":"Nava F, Premi S, Manzato E, et al. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions. J Psychoactive Drugs. 2006;38(3):211\u20137.","journal-title":"J Psychoactive Drugs."},{"issue":"1","key":"158_CR61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","volume":"70","author":"F Caputo","year":"2003","unstructured":"Caputo F, Addolorato G, Lorenzini F, et al. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003;70(1):85\u201391.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"158_CR62","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.phrs.2008.03.001","volume":"57","author":"L Stella","year":"2008","unstructured":"Stella L, Addolorato G, Rinaldi B, et al. An open randomized study of the treatment of escitalopram alone and combined with \u03b3-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol Res. 2008;57(4):312\u20137.","journal-title":"Pharmacol Res."},{"issue":"12","key":"158_CR63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","volume":"17","author":"F Caputo","year":"2007","unstructured":"Caputo F, Addolorato G, Stoppo M, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol. 2007;17(12):781\u20139.","journal-title":"Eur Neuropsychopharmacol."},{"issue":"4","key":"158_CR64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.alcalc.a008160","volume":"31","author":"G Addolorato","year":"1996","unstructured":"Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. Alcohol Alcohol. 1996;31(4):341\u20135.","journal-title":"Alcohol Alcohol."},{"issue":"1","key":"158_CR65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0376-8716(98)00094-5","volume":"53","author":"G Addolorato","year":"1998","unstructured":"Addolorato G, Cibin M, Caputo F, et al. \u03b3-Hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients. Drug Alcohol Depend. 1998;53(1):7\u201310.","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"158_CR66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/02791072.2001.10400478","volume":"33","author":"I Maremmani","year":"2001","unstructured":"Maremmani I, Lamanna F, Tagliamonte A. Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics. J Psychoactive Drugs. 2001;33(2):135\u201342.","journal-title":"J Psychoactive Drugs."},{"issue":"7","key":"158_CR67","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/ijerph8072816","volume":"8","author":"AGI Maremmani","year":"2011","unstructured":"Maremmani AGI, Pani PP, Rovai L, et al. Long-term \u03b3-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environ Res Public Health. 2011;8(7):2816\u201327.","journal-title":"Int J Environ Res Public Health."},{"issue":"6","key":"158_CR68","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2010.12.005","volume":"21","author":"F Caputo","year":"2011","unstructured":"Caputo F, Francini S, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol. 2011;21(6):450\u20136.","journal-title":"Eur Neuropsychopharmacol."},{"key":"158_CR69","author":"F Caputo","year":"2013","unstructured":"Caputo F, Del Re A, Brambilla R, et al. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: a pilot study. J Psychopharmacol (Oxf). 2013. doi: 10.1177\/0269881113504015 .","journal-title":"J Psychopharmacol (Oxf)."},{"issue":"8","key":"158_CR70","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","volume":"23","author":"F Caputo","year":"2009","unstructured":"Caputo F, Francini S, Stoppo M, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol (Oxf). 2009;23(8):883\u201390.","journal-title":"J Psychopharmacol (Oxf)."},{"issue":"Suppl 1","key":"158_CR71","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/alcalc\/agt101","volume":"48","author":"O Lesch","year":"2013","unstructured":"Lesch O, Skala K, Addolorato G, et al. Sodium oxybate in alcohol withdrawal: results from the GATE 1 study [abstract no. SAT2.1]. Alcohol Alcohol. 2013;48(Suppl 1):i33\u20134.","journal-title":"Alcohol Alcohol."},{"key":"158_CR72","unstructured":"European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf . Accessed 10 Sep 2013."},{"key":"158_CR73","unstructured":"AOP Orphan Pharmaceuticals AG. Ethylex (naltrexone) film-coated tablets: Irish summary of product characteristics. 2011. http:\/\/www.imb.ie\/images\/uploaded\/swedocuments\/LicenseSPC_PA0934-002-001_05072012085042.pdf . Accessed 10 Oct 2013."},{"key":"158_CR74","unstructured":"Actavis UK Ltd. Antabuse tablets (disulfiram): UK summary of product characteristics. 2012. http:\/\/beta.medicines.org.uk\/emc\/medicine\/519 . Accessed 10 Oct 2013."},{"key":"158_CR75","unstructured":"Merck Serono. Campral EC (acamprosate): UK summary of product characteristics. 2012. http:\/\/beta.medicines.org.uk\/emc\/medicine\/1042 . Accessed 10 Oct 2013."},{"issue":"9","key":"158_CR76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","volume":"27","author":"GM Keating","year":"2013","unstructured":"Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs. 2013;27(9):761\u201372.","journal-title":"CNS Drugs."},{"issue":"9","key":"158_CR77","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0269881110363315","volume":"24","author":"Z N\u00e9meth","year":"2010","unstructured":"N\u00e9meth Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol (Oxf). 2010;24(9):1281\u20137.","journal-title":"J Psychopharmacol (Oxf)."},{"issue":"Suppl 1","key":"158_CR78","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/alcalc\/agt095","volume":"48","author":"F Nava","year":"2013","unstructured":"Nava F, Bravin S, Borroni G, et al. A retrospective study on the use of sodium oxybate in northern Italy [abstract no. SAT2.4]. Alcohol Alcohol. 2013;48(Suppl 1):i34.","journal-title":"Alcohol Alcohol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0158-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0158-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:22:54Z","timestamp":1597130574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0158-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,4]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0158-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,4]]}}}